3005961
print

C5 Inhibitors Drug Monitoring Panel

C5 INH PAN
Example Reports
Abnormal
Normal

Ordering Recommendation

Use to monitor complement blockage in patients treated with C5 inhibitor drugs.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Plain red.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 2.0 mL serum to an ARUP standard transport tube and freeze immediately. (Min: 2.0 mL)

Storage/Transport Temperature

CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.

Unacceptable Conditions

Specimens received refrigerated, ambient, lipemic specimens, or grossly hemolyzed specimens. Serum separator tubes. Specimens collected using calcium-binding anticoagulants (i.e., EDTA, ACD).

Remarks
Stability

Refer to individual components.

Methodology

Quantitative Turbidimetric/Quantitative Radial Immunodiffusion

Performed

Tue, Fri

Reported

1-9 days

Reference Interval

Test Number
 Components
 Reference Interval
  Complement Activity, Total Turbidimetric 38.7-89.9 U/mL
  Complement C5, Concentration 7-20 mg/dL
  Alternative Complement Pathway Activity 31 percent normal or greater
  Complement C5, Functional 23.0 U/mL or greater

Interpretive Data




Component
Interpretation
Complement Activity, Total Turbidimetric Low: 38.6 U/mL or less 
Normal: 38.7-89.9 U/mL 
High: 90.0 U/mL or greater
Complement C5, Functional Low: 22.9 U/mL or less
Low-Normal: 23.0-28.3 U/mL
Normal: 28.4 U/mL or greater
Alternative Complement Pathway Activity See Report
C5 Inhibitors Drug Monitoring Pan Interp Patients treated with C5 inhibitors may show decreased/absent activity in total complement functional assay (CH50), alternative pathway functional assay (AH50), and C5 functional assay with normal or elevated C5 protein concentrations. Normal CH50, AH50, or C5 functional activity with normal or elevated C5 protein concentrations indicate inadequate complement blockage. Serial measurements are recommended when monitoring treatment efficacy. Decreases in both C5 concentration and C5 functional activity suggests a secondary consumption process or C5 deficiency. Repeat testing using a new specimen is suggested if in vitro complement activation and consumption of components due to conditions of collection, transport, and/or handling is suspected.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
08/21/2023
X
X
X
X
N/A

CPT Codes

86160; 86161 x2; 86162

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0050156 Complement C5, Concentration 4505-4
2005374 Alternative Complement Pathway Activity 74520-8
3002576 Complement Activity, Total Turbidimetric 4532-8
3005962 Complement C5, Functional 60472-8
3006097 C5 Inhibitors Drug Monitoring Pan Interp 48767-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Ravulizumab
  • C5 inhibitor
  • Complement blocking
  • AH50
  • anti-C5
  • Complement C5 functional
  • Complement monitoring
  • CH50 total
  • concentration
  • Eculizumab
  • Complement C5
C5 Inhibitors Drug Monitoring Panel